Skip to main content
Signal8
Launch Terminal

LB PHARMACEUTICALS INC (LBRX)

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

LB Pharmaceuticals Inc Common Stock logo

LB Pharmaceuticals Inc Common Stock

NASDAQ:LBRXHealthcare
-1.12%$39.70
AH$41.19+3.75%vs close
Mkt Cap$1.28B
Float24.22M
O/S32.26M
Vol
$ Vol
RVOL
Inst Own92.5%
SI23.0%
Earnings
Dilution
LB Pharmaceuticals Inc Common Stock logoNASDAQ:LBRX$39.70-1.12%
FormDescription
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
EFFECT
Notice of Effectiveness
POS AM
Post-Effective Amendment
S-3ASR
SEC Filing
4
3
Initial Statement of Beneficial Ownership
424B3
Prospectus
1
8-K
5.02,7.01,9.01
2
3
Initial Statement of Beneficial Ownership
424B3
Prospectus
4
8-K
5.02,7.01,9.01
3
13G/A
Beneficial Ownership Report (Amended)
424B3
Prospectus
6
10-Q
Quarterly Report
7
8-K
2.02,9.01
4
4
Statement of Changes in Beneficial Ownership
13G/A
Beneficial Ownership Report (Amended)
424B3
Prospectus
1
8-K
1.01,3.02,7.01,9.01
2
424B3
Prospectus
8-K
8.01,9.01
13G
Beneficial Ownership Report
424B3
Prospectus
2
8-K
5.02,9.01

1-25 of 141

…

Recent SEC filings with analysis

    LB PHARMACEUTICALS INC (LBRX) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8